Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: Results From the National Cancer Data Base

Journal of Clinical Oncology

Volumn 33, Issue 36, 2015, Pages 4267-4275

  Killelea, Brigid K ^a,b   Yang, Vicky Q ^c   Wang, Shi Yi ^c   Hayse, Brandon ^a   Mougalian, Sarah ^a,b   Horowitz, Nina R ^b   Chagpar, Anees B ^a,b   Pusztai, Lajos ^a,b   Lannin, Donald R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMORBIDITY; DATA BASE; ETHNICITY; EUROPEAN AMERICAN; FEMALE; HEALTH INSURANCE; HISPANIC; HUMAN; INCOME; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ASIAN AMERICAN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CAUCASIAN; COMPARATIVE STUDY; ECONOMICS; EPIDEMIOLOGY; ETHNOLOGY; FACTUAL DATABASE; INSURANCE; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN AMERICANS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES;

EID: 84957579710     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.7801     Document Type: Article

References (20)

1. Silber JH, Rosenbaum PR, Clark AS, et al: Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389-397, 2013
2. Cunningham JE, Montero AJ, Garrett-Mayer E, et al: Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 21:399-409, 2010
3. DeSantis C, Jemal A, Ward E: Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes Control 21:1445-1450, 2010
4. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute, 2013
5. Copeland G, Lake A, Firth R, et al: Cancer in North America: 2006-2010. Volume One: Combined Cancer Incidence for the United States, Canada, and North America. Springfield, IL, North American Association of Central Cancer Registries, 2013
6. Killelea BK, Yang VQ, Mougalian S, et al: Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: Results from the National Cancer Database. J Am Coll Surg 220:1063-1069, 2015
7. Mougalian SS, Soulos PR, Killelea BK, et al: Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121:2544-2552, 2015
8. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
9. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988
10. Mauri D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97:188-194, 2005
11. Kuerer HM, Singletary SE, Buzdar AU, et al: Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 182:601-608, 2001
12. Tichy JR, Deal AM, Anders CK, et al: Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667-674, 2015
13. Chavez-MacGregor M, Litton J, Chen H, et al: Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. Cancer 116:4168-4177, 2010
14. Balmanoukian A, Zhang Z, Jeter S, et al: African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol 27:e35-e37, author reply e38-e39, 2009
15. Dawood S, Broglio K, Kau SW, et al: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220-226, 2009
16. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
17. Dawood S, Broglio K, Esteva FJ, et al: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20:621-627, 2009
18. Albain KS, Unger JM, Crowley JJ, et al: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984-992, 2009
19. Masuda H, Baggerly KA, Wang Y, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19:5533-5540, 2013
20. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007